However, no approved targeted therapy regimens are available for lung squamous patients in spite of distinct genetic alterations identified in the tumor type, including alterations in TP53, PIK3CA, CDKN2A, MLL2, PTEN,KEAP1, NFE2L2,DDR2,FGFR1, PDGFRA, SOX2, and CCND1 [9–15]. The gene discussed is DDR2; the disease is neoplasm.